texas oncology more breakthroughs. more victories

Austin Midtown Research & Clinical Trials

Texas Oncology-Austin Midtown participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin Midtown (Expand)

Biliary Cancer

STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements Read Moreabout STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

Phase: II

Bladder Cancer

QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Phase: II

Brain Cancer

Ph2 study of BPM31510 in newly diagnosed GB

A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11) Read Moreabout Ph2 study of BPM31510 in newly diagnosed GB

Phase: II

Breast Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph2 study of PCS6422 with advanced met breast cancer

A Phase 2 Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer (PCS6422-BC-01) Read Moreabout Ph2 study of PCS6422 with advanced met breast cancer

Phase: II

Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

Phase: III

Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001) Read Moreabout Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

Phase: III

Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast

A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) Read Moreabout Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast

Phase: III

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 study of standard endocrine therapy with breast cancer

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)

GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD) Read Moreabout Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)

Open-label Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (TOL2506A-EXT) Read Moreabout Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)

Phase: III

Retrospective analysis of adherence and patient reported outcomes for ribociclib (ribo) patients using ReX Technology Platform

Colon Cancer

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Endometrial Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Esophageal Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Fallopian Tube Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Gastric Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Head and Neck Cancer

STAR Ph3 study to evaluate to treat patients with HNSCC

A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC

Phase: III

Ph3 study of pembro in HNSCC in the disease without curative therapy available

A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03) Read Moreabout Ph3 study of pembro in HNSCC in the disease without curative therapy available

Phase: III

Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)

A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) D798EC00001 Read Moreabout Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)

Phase: III

Leukemia

Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)

A Phase 3 Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib or Acalabrutinib in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) (MK-1026-011) Read Moreabout Ph3 Study of Nemtabrutinib w/untreated Lymphocytic Leukemia (BELLWAVE-011)

Phase: III

Ph2b/3 Study to evaluate and optimization in combo with untreated CLL

A Prospective Open-Label Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287) Read Moreabout Ph2b/3 Study to evaluate and optimization in combo with untreated CLL

Phase: II/III

Lung Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005) Read Moreabout Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC

Phase: II

Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II/III

STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217) Read Moreabout STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC

Phase: III

Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)

A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001) Read Moreabout Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)

Phase: III

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase: III

Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC

A Randomized Double-Blind Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS) (CA245-0001) Read Moreabout Ph3 trial of BMS-986489 in combo with carboplatin in extensive stage SCLC

Phase: III

Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non- small Cell Lung Cancer (HARMONi-3) (SMT112-3003) Read Moreabout Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

Phase: III

Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)

A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007) Read Moreabout Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7)

Phase: III

Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216) Read Moreabout Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

Phase: III

Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC

SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression (J3M-MC-JZQB) Read Moreabout Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC

Phase: III

Lymphomas

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma

A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003) Read Moreabout Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma

Phase: III

Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145) Read Moreabout Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma

Phase: III

Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202] Read Moreabout Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3)

Phase: II

Melanoma

Ph1/1b Study of WTX-124 Mono or + Pembro in Select Solid Tumors

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors (WTX-124x2101) Read Moreabout Ph1/1b Study of WTX-124 Mono or + Pembro in Select Solid Tumors

Phase: I/II

Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122) Read Moreabout Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

Phase: III

Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2

A randomized open-label Phase 3 study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to physician's choice of therapy (dacarbazine temozolomide or trametinib monotherapy) with a dose optimization lead-in [SEACRAFT-2] (ERAS-254-02) Read Moreabout Ph3 Study of Naporafebnib + Trametinib in met NRAS Cutaneous Melanoma SEACRAFT-2

Phase: III

Miscellaneous

Phase 1 Open-Label Study to Evaluate Safety and Determine the Maximum Tolerated Dose Of IBRX-042 In Subjects With HPV-Associated Tumors

Phase: I

Myelomas

SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165)

64007957MMY2010/MM165: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal) Read Moreabout SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165)

Phase: II

Ph1 study of ABBV-383 in subjects with relapsed or refractory MM

A Multicenter Phase 1b Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma (M24-108) Read Moreabout Ph1 study of ABBV-383 in subjects with relapsed or refractory MM

Phase: I

Ovarian Cancer

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Pancreatic Cancer

Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001) Read Moreabout Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ

Phase: I

Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302) Read Moreabout Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC)

Phase: III

Peritoneal Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Prostate Cancer

Ph2 XmAB20717 GYN malig & CRPC

A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer (XmAb20717-05) Read Moreabout Ph2 XmAB20717 GYN malig & CRPC

Phase: II

Ph3 study of MK-5684 versus alternative NHA in mCRPC

A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004) Read Moreabout Ph3 study of MK-5684 versus alternative NHA in mCRPC

Phase: III

Ph3 BMS-986365 study of comparing a second androgen receptor pathway inhibitor in mCRPC

A Phase 3 Two-part Randomized Open-label Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI) in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (CA071-1000) Read Moreabout Ph3 BMS-986365 study of comparing a second androgen receptor pathway inhibitor in mCRPC

Phase: III

Rectal Cancer

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Renal Cancer

Ph1/1b Study of WTX-124 Mono or + Pembro in Select Solid Tumors

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors (WTX-124x2101) Read Moreabout Ph1/1b Study of WTX-124 Mono or + Pembro in Select Solid Tumors

Phase: I/II

Skin Cancer

Ph1/1b Study of WTX-124 Mono or + Pembro in Select Solid Tumors

A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors (WTX-124x2101) Read Moreabout Ph1/1b Study of WTX-124 Mono or + Pembro in Select Solid Tumors

Phase: I/II

Solid Tumors

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)

Phase: I/II

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Ph1a/b LOXO-435 in Solids with FGFR3 Alterations

AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS (LOXO-FG3-22001) Read Moreabout Ph1a/b LOXO-435 in Solids with FGFR3 Alterations

Phase: I

STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01) Read Moreabout STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors

Phase: IV

Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001) Read Moreabout Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors

Phase: I/II

Ph2 Tumor-Agnostic Precision TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932) Read Moreabout Ph2 Tumor-Agnostic Precision TAPISTRY

Phase: II

Urothelial Cancer

Ph2 Study of Livmoniplimab in combination with subjects met Urothelial Carcinoma

A Phase 2 Open-Label Randomized Study of Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Subjects with Metastatic Urothelial Carcinoma (M25-204) Read Moreabout Ph2 Study of Livmoniplimab in combination with subjects met Urothelial Carcinoma

Phase: II

Ph1a/b LOXO-435 in Solids with FGFR3 Alterations

AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS (LOXO-FG3-22001) Read Moreabout Ph1a/b LOXO-435 in Solids with FGFR3 Alterations

Phase: I